PMID- 22240216
OWN - NLM
STAT- MEDLINE
DCOM- 20120601
LR  - 20191210
IS  - 1776-2588 (Electronic)
IS  - 0761-8425 (Linking)
VI  - 29
IP  - 1
DP  - 2012 Jan
TI  - [Pemetrexed salvage chemotherapy for NSCLC: implementation study].
PG  - 21-7
LID - 10.1016/j.rmr.2011.11.003 [doi]
AB  - BACKGROUND: Registration trials demonstrated the activity of pemetrexed in non 
      small cell lung carcinoma (NSCLC) either in combination with first-line agents or 
      in monotherapy for salvage treatment. The aim of our implementation study was to 
      verify, in an unselected population, the results obtained with pemetrexed salvage 
      chemotherapy in clinical practice. PATIENTS AND METHODS: The charts of all 
      patients diagnosed with NSCLC, receiving pemetrexed for progressive disease after 
      at least one previous course of chemotherapy, were retrospectively reviewed in 
      two academic institutions. Response was assessed according to WHO and toxicity 
      using the CTCAE and WHO criteria. RESULTS: Between November 2004 and 
      September 2009, 84 patients were given pemetrexed as second, third or greater 
      than third line therapy (n=18/14/52). Intent-to-treat response rate was 11.9% 
      (95% CI, 5%-18.8%). Median progression-free survival was 2.2 months and median 
      survival time was 6.4 months. The most frequent grade 3-5 toxicity was 
      neutropenia (23.9%). CONCLUSION: Salvage chemotherapy with pemetrexed for 
      progressing NSCLC confirmed, in an unselected population, who had been 
      extensively treated previously, the level of activity observed in registration 
      trials although a significant toxicity was noted.
CI  - Copyright (c) 2011 SPLF. Published by Elsevier Masson SAS. All rights reserved.
FAU - Jungels, C
AU  - Jungels C
AD  - Departement des soins intensifs et oncologie thoracique, centre des tumeurs, 
      institut Jules-Bordet, universite Libre de Bruxelles, 1, rue Heger-Bordet, 1000 
      Bruxelles, Belgique.
FAU - Berghmans, T
AU  - Berghmans T
FAU - Meert, A P
AU  - Meert AP
FAU - Lafitte, J J
AU  - Lafitte JJ
FAU - Scherpereel, A
AU  - Scherpereel A
FAU - Sculier, J P
AU  - Sculier JP
LA  - fre
PT  - Evaluation Study
PT  - Journal Article
PT  - Multicenter Study
TT  - Traitement de rattrapage par pemetrexed pour les CBNPC: etude retrospective 
      d'implementation.
DEP - 20111214
PL  - France
TA  - Rev Mal Respir
JT  - Revue des maladies respiratoires
JID - 8408032
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Glutamates)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 5Z93L87A1R (Guanine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology
MH  - Chemotherapy, Adjuvant
MH  - Disease Progression
MH  - Female
MH  - Glutamates/*therapeutic use
MH  - Guanine/*analogs & derivatives/therapeutic use
MH  - Guideline Adherence
MH  - Health Plan Implementation
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Pemetrexed
MH  - Retrospective Studies
MH  - Salvage Therapy
MH  - Survival Analysis
EDAT- 2012/01/14 06:00
MHDA- 2012/06/02 06:00
CRDT- 2012/01/14 06:00
PHST- 2011/02/11 00:00 [received]
PHST- 2011/06/21 00:00 [accepted]
PHST- 2012/01/14 06:00 [entrez]
PHST- 2012/01/14 06:00 [pubmed]
PHST- 2012/06/02 06:00 [medline]
AID - S0761-8425(11)01458-6 [pii]
AID - 10.1016/j.rmr.2011.11.003 [doi]
PST - ppublish
SO  - Rev Mal Respir. 2012 Jan;29(1):21-7. doi: 10.1016/j.rmr.2011.11.003. Epub 2011 
      Dec 14.